Gilead Sciences
GILD
$143.72
-0.75%
Gilead Sciences Inc. is a biopharmaceutical company that develops and markets therapies for life-threatening infectious diseases, with a core focus on HIV and hepatitis B and C, and is expanding into oncology through acquisitions such as Kite and Immunomedics. As a market leader in HIV treatment and prevention, Gilead holds a dominant position with a portfolio that includes Biktarvy and Descovy, while also advancing CAR-T therapies like Yescarta and Trodelvy in oncology. The current investor narrative centers on Gilead's aggressive acquisition strategy to bolster its pipeline, including the $7.8 billion Arcellx deal and the $3.15 billion Tubulis acquisition, alongside recent approval of Bixlenvo for HIV, which has raised sales guidance and fueled optimism about growth. However, setbacks such as the discontinuation of a Trodelvy-Keytruda lung cancer trial highlight the high-risk nature of drug development, creating a mix of enthusiasm and caution among investors.…
GILD
Gilead Sciences
$143.72
Related headlines
Investment Opinion: Should I buy GILD Today?
Based on the analysis, GILD is rated a Buy. The stock offers a compelling risk/reward with a forward PE of 15.27x, which is below the market average, and a consensus analyst target price of $157.41, implying about 4.3% upside from the current price of $150.995. The company's strong HIV franchise, robust margins, and strategic acquisitions in oncology support a positive outlook.
Sign up to view all
GILD 12-Month Price Forecast
The AI model assesses GILD as a bullish opportunity with medium confidence. The company's strong cash generation, attractive valuation, and strategic pipeline investments outweigh the risks of clinical setbacks and concentration. The model would upgrade its stance if oncology pipeline data improves or if revenue growth accelerates above 6%. Conversely, a downgrade would occur if a major trial fails or if HIV sales decline unexpectedly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $158.15 and implied upside of +10.0% versus the current price.
Average Target
$158.15
0 analysts
Implied Upside
+10.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$123 - $180
Analyst target range
The target price range spans from a low of $123.00 to a high of $180.00, indicating a wide dispersion of 46% from low to high, reflecting significant uncertainty about Gilead's future prospects. The high target of $180 assumes successful pipeline execution and market share gains in oncology, while the low target of $123 prices in potential setbacks in drug development and competitive pressures. Recent institutional ratings show a mix of reaffirmations and upgrades, with no downgrades in the past six months, suggesting a stable to improving sentiment. The wide range between low and high targets highlights the high-risk, high-reward nature of the stock, driven by binary outcomes from clinical trials and M&A integration.
Bulls vs Bears: GILD Investment Factors
Gilead presents a compelling mix of a dominant HIV franchise, strong profitability, and an attractive forward valuation, but faces significant risks from pipeline execution and concentration. The bull case is supported by solid fundamentals and a clear growth strategy, while the bear case hinges on clinical failures and potential overvaluation. Currently, the evidence slightly favors the bulls, given the low forward PE and robust cash flow, but the key tension lies in whether the oncology pipeline can deliver meaningful growth to offset HIV's eventual slowdown. The outcome of upcoming clinical trials and integration of recent acquisitions will be decisive.
Bullish
- Strong HIV franchise growth: HIV product sales reached $5.03 billion in Q1 2026, driving overall revenue up 4.39% YoY. The recent approval of Bixlenvo and raised 2026 HIV sales guidance signal continued momentum in the core therapeutic area.
- Attractive valuation with forward PE discount: The trailing PE is 17.94x, but the forward PE is 15.27x, implying expected earnings growth. Based on estimated EPS of $13.09, the forward PE drops to ~11.5x, a significant discount to the broader market and historical levels.
- Robust profitability and cash flow: Gross margin is a stellar 78.8%, operating margin is 39.7%, and net margin is 28.9%. Free cash flow over the trailing twelve months is $10.23 billion, providing ample resources for dividends, buybacks, and acquisitions.
- Aggressive pipeline expansion via M&A: Recent deals include the $7.8 billion Arcellx acquisition for a next-gen myeloma CAR-T therapy and the $3.15 billion Tubulis deal, strengthening the oncology pipeline. These moves are expected to boost earnings from 2028, according to analysts.
Bearish
- High dependence on HIV franchise: HIV products account for over 70% of total revenue, creating concentration risk. Any loss of market share, pricing pressure, or patent cliff could significantly impact the top line.
- Clinical trial setbacks in oncology: The discontinuation of the Trodelvy-Keytruda lung cancer trial due to mixed results highlights the binary risk in drug development. This failure could limit growth expectations for the oncology segment.
- Elevated debt and acquisition integration risk: Debt-to-equity stands at 1.10, and the company has been on an acquisition spree, including the $7.8 billion Arcellx deal. Integration challenges and potential overpayment could strain financials and dilute shareholder value.
- Potential overvaluation after strong run: The stock is trading near its 52-week high of $157.29, with a price-to-sales ratio of 5.19 and price-to-book of 6.73. If growth fails to materialize, the stock could be vulnerable to multiple compression.
GILD Technical Analysis
Gilead's stock is in a robust uptrend, with a 1-year price change of +33.9%, significantly outperforming the S&P 500's +18.65% over the same period. The current price of $150.995 sits near the upper end of its 52-week range, at approximately 96% of the high of $157.29 and 39% above the low of $108.46. This positioning near the highs indicates strong momentum, though it also suggests the stock may be approaching overbought conditions, warranting caution for new entries.
Beta
0.35
0.35x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$108-$157
Price range past year
Annual Return
+21.9%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | +5.8% | -1.1% |
| 3m | +14.4% | +3.0% |
| 6m | -0.9% | +15.4% |
| 1y | +21.9% | +16.2% |
| ytd | +18.2% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Gilead's revenue trajectory shows steady growth, with Q1 2026 revenue of $6.96 billion, up 4.39% year-over-year from $6.667 billion in Q1 2025. This growth is driven by strong HIV product sales, which totaled $5.03 billion in the quarter, and cell therapy products contributing $482 million, while Veklury sales declined to $144 million. The multi-quarter trend shows revenue fluctuating between $6.67 billion and $7.92 billion over the past year, with Q4 2025 peaking at $7.924 billion, indicating a stable but not accelerating growth pattern.
Quarterly Revenue
$7.0B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
79.2%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Given Gilead's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 17.94x, while the forward PE is 15.27x, indicating the market expects earnings growth. The gap between trailing and forward PE suggests an anticipated increase in EPS, which is supported by the estimated EPS average of $13.09 for the next fiscal year, implying a forward PE of approximately 11.5x based on the current price. This discount to the trailing multiple reflects optimism about future profitability.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 1.10, which could limit financial flexibility, especially if interest rates remain elevated. The company's reliance on a few key products, particularly in HIV, exposes it to revenue concentration risk; any disruption in that franchise would have outsized effects. While free cash flow is strong at $10.23 billion, the aggressive acquisition strategy could lead to integration challenges and potential write-downs if pipeline assets fail. Additionally, the payout ratio of 47% indicates a commitment to dividends, but this could strain cash flow if earnings decline.
FAQ
The key risks include: 1) Clinical trial failures, as seen with the Trodelvy-Keytruda lung cancer trial, which could derail oncology growth. 2) Concentration risk in HIV, which accounts for over 70% of revenue; any loss of market share or patent issues would be significant. 3) High debt levels (debt-to-equity of 1.10) and integration risks from multiple acquisitions. 4) Regulatory and political risks, such as drug pricing reforms or tariffs. The most severe risk is a major pipeline failure, which could lead to a 20-30% drop in the stock price.
The 12-month forecast is moderately bullish. The base case, with a 50% probability, sees the stock trading in the $145-$160 range, aligning with the analyst average target of $157.41. The bull case (25% probability) targets $165-$180, driven by successful pipeline execution, while the bear case (25% probability) sees $123-$135 if setbacks occur. The most likely scenario is steady growth with the stock hovering near current levels, as the market awaits clearer evidence on oncology progress.
Based on forward earnings, GILD is undervalued relative to its growth prospects. The forward PE of 15.27x is below the S&P 500's average of around 20x, and the PEG ratio of 0.01 is extremely low, though this is distorted by low expected growth. Compared to its own history, the stock trades at a discount to its five-year average PE. The market appears to be pricing in modest growth and high risk, but if the oncology pipeline succeeds, the stock could re-rate higher.
GILD is a good buy for investors with a medium-to-long-term horizon who are comfortable with biotech risk. The stock offers a forward PE of 15.27x, which is attractive relative to the market, and a consensus analyst target of $157.41, implying about 4.3% upside. However, the stock is near its 52-week high, so there is limited short-term upside, and the main downside risk is a clinical failure or competitive pressure in HIV. For those seeking a defensive healthcare play with growth optionality, GILD is a reasonable addition.
GILD is more suitable for long-term investment, given its low beta of 0.35 and defensive characteristics. The stock offers a dividend yield of 2.6% and has shown steady, albeit modest, growth. Short-term trading is possible given the recent momentum, but the stock's high valuation relative to its near-term growth makes it less attractive for quick gains. A minimum holding period of 3-5 years is recommended to allow the oncology pipeline to mature and for acquisitions to contribute to earnings.